Pfizer starts Phase II/III trial of oral antiviral for Covid-19 prevention
The trial will have 2,660 healthy adult subjects who are living in the same household as a person with a Covid-19 infection.
Clinical Trials
PTF: Unpacking innovation in biologics
In this issue: Unpacking the challenge of complex biologics, using bacteria to fight breast cancer,...
Merck and Ridgeback’s molnupiravir rollout difficult to map in uncertain Covid-19 landscape
Questions about oral molnupiravir's deployment still loom large as clinicians await crucial late-stage trial results.
J&J’s data confirms robust and durable protection of Covid-19 vaccine
Antibody levels increased to 12-fold after four weeks of administering a booster shot of the...
Pfizer and BioNTech report positive Covid-19 vaccine trial data in children
The vaccine demonstrated a favourable safety profile and was well-tolerated in children aged five to...
Promising therapeutics on horizon for recurrent and metastatic cervical cancer
Alternative treatment options for recurrent and metastatic cervical cancer can transform the landscape and satisfy unmet needs.
Oral molnupiravir has at least 350 patients left to recruit in Phase III Covid-19 trial
As breakthrough mild-to-moderate Covid-19 cases continue to rise, all eyes are on Merck and Ridgeback Biotherapeutics’ antiviral.
Korean MFDS approves Celltrion’s regdanvimab for Covid-19 treatment
In the Phase III trial, regdanvimab demonstrated a 72% reduction in the risk of Covid-19-linked hospitalisation or mortality.
Covid-19 mRNA vaccines for kids likely to be safe and effective but vigilance needed
Experts point to uncharted factors in COVID-19 vaccine research in kids as mRNA jab developers reveal their authorisation plans.
CinnaGen protein subunit Covid-19 vaccine Phase III results likely within two months
Race to be the first widely distributed protein subunit Covid-19 vaccine heats up with Vaxine nipping at Novavax’s heels.
Promising drugs in clinical development for cystic fibrosis
GlobalData's cystic fibrosis market forecast focuses on five products expected to be licensed in the seven major markets by 2030.
